ES2194677T3 - Suspensiones de trovafloxacina de administracion por via oral. - Google Patents

Suspensiones de trovafloxacina de administracion por via oral.

Info

Publication number
ES2194677T3
ES2194677T3 ES00304550T ES00304550T ES2194677T3 ES 2194677 T3 ES2194677 T3 ES 2194677T3 ES 00304550 T ES00304550 T ES 00304550T ES 00304550 T ES00304550 T ES 00304550T ES 2194677 T3 ES2194677 T3 ES 2194677T3
Authority
ES
Spain
Prior art keywords
suspensions
crystals
trovafloxacine
administration via
via oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00304550T
Other languages
English (en)
Inventor
Douglas John Allen
Sojka Sonja Sekulic
Daniel Ray Arenson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Application granted granted Critical
Publication of ES2194677T3 publication Critical patent/ES2194677T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

Un cristal de ión bipolar de trovafloxacina de la **fórmula** con una forma de tablillas de seis caras, que presenta el siguiente patrón de difracción de rayos X de torta húmeda. Nº de 1 2 3 4 5 6 7 8 9 pico 2q(°) 6, 2 8, 6 11, 12, 12, 8 16, 16, 8 18, 19, 5 Cu 8 4 1 6 espacio 14, 3 10, 7, 5 7, 1 6, 9 5, 5 5, 3 4, 8 4, 5 d 0 Nº de 10 11 12 13 14 15 16 17 18 pico 2q(°) 20, 1 22, 23, 26, 28, 3 29, 37, 7 39, Cu 6 7 7 9 0 espacio 4, 4 4, 1 3, 8 3, 3 3, 2 3, 0 2, 4 2, 3 d
ES00304550T 1999-06-04 2000-05-30 Suspensiones de trovafloxacina de administracion por via oral. Expired - Lifetime ES2194677T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13746399P 1999-06-04 1999-06-04

Publications (1)

Publication Number Publication Date
ES2194677T3 true ES2194677T3 (es) 2003-12-01

Family

ID=22477550

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00304550T Expired - Lifetime ES2194677T3 (es) 1999-06-04 2000-05-30 Suspensiones de trovafloxacina de administracion por via oral.

Country Status (10)

Country Link
US (1) US6239141B1 (es)
EP (1) EP1057828B1 (es)
JP (1) JP3465820B2 (es)
AT (1) ATE234835T1 (es)
BR (1) BR0002577A (es)
CA (1) CA2311112A1 (es)
DE (1) DE60001687T2 (es)
DK (1) DK1057828T3 (es)
ES (1) ES2194677T3 (es)
PT (1) PT1057828E (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20010635A1 (es) 1999-10-08 2001-08-15 Smithkline Beecham Corp Inhibidores de fab i utiles para el tratamiento de infecciones bacterianas
BR0207930A (pt) * 2001-03-05 2004-03-02 Ortho Mcneil Pharm Inc Composições farmacêuticas lìquidas com sabor mascarado
ES2320984T3 (es) * 2001-04-06 2009-06-01 Affinium Pharmaceuticals, Inc. Inhibidores de fab i.
US20030068829A1 (en) * 2001-06-25 2003-04-10 Symyx Technologies, Inc. High throughput crystallographic screening of materials
MXPA04000294A (es) * 2001-07-10 2004-05-04 Pharmacia & Upjhon Company Tiacin oxazolidinonas cristalinas.
CA2455050C (en) 2001-08-15 2007-02-20 Pharmacia & Upjohn Company Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene) methyl]-2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
PL212421B1 (pl) * 2002-03-12 2012-09-28 Bristol Myers Squibb Co Kompozycja farmaceutyczna w postaci zawiesiny kwasowego leku i sposób jej wytwarzania oraz sposób maskowania gorzkiego lub innego nieprzyjemnego smaku leku
US8367098B2 (en) * 2002-04-30 2013-02-05 The Population Council, Inc. Unique combinations of antimicrobial compositions
AU2003245252A1 (en) * 2002-04-30 2003-11-17 Fmc Corporation Carrageenan based antimicrobial compositions
ES2518316T3 (es) 2002-12-06 2014-11-05 Debiopharm International Sa Compuestos heterocíclicos, métodos de fabricación de los mismos y su uso en terapia
CA2519429C (en) 2003-03-17 2013-08-06 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
US20050031700A1 (en) * 2003-07-18 2005-02-10 Sanatarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
ES2515101T3 (es) 2004-06-04 2014-10-29 Debiopharm International Sa Derivados de acrilamida como agentes antibióticos
KR20080075027A (ko) * 2005-12-05 2008-08-13 아피늄 파마슈티컬스, 인크. Ｆａｂｉ 억제제 및 항박테리아제로서의헤테로시클릴아크릴아미드 화합물
EP2054422B1 (en) 2006-07-20 2017-06-14 Debiopharm International SA Acrylamide derivatives as fab i inhibitors
US8263613B2 (en) * 2007-02-16 2012-09-11 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab I inhibitors
NZ702695A (en) 2012-06-19 2015-10-30 Debiopharm Int Sa Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
US10751351B2 (en) 2016-02-26 2020-08-25 Debiopharm International S.A. Medicament for treatment of diabetic foot infections

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164402A (en) 1989-08-16 1992-11-17 Pfizer Inc Azabicyclo quinolone and naphthyridinone carboxylic acids
US5266559A (en) 1989-10-27 1993-11-30 Firmenich S.A. Use of unsaturated macrocyclic lactones as perfuming ingredients
US5391763A (en) 1990-07-11 1995-02-21 Pfizer Inc. 3-aza-bicyclo[3.1.0]hexanes which are intermediates for anti-bacterial azabicyclo quinolone carboxylic acids
TW271400B (es) 1992-07-30 1996-03-01 Pfizer
US5763454A (en) 1995-06-06 1998-06-09 Pfizer, Inc. Crystal form of anhydrous 7-( 1α,5α,6α!-6-amino-3-azabicyclo 3.1.0!hex-3-yl)-6-fluoro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1,8 naphthyridine-3-carboxylic acid, methanessulfonic acid salt
ATE208790T1 (de) * 1995-08-29 2001-11-15 Pfizer Polymorphs von prodrug 6-n(l-ala-l-ala)- trovafloxacin
NZ312199A (en) 1995-08-29 1999-06-29 Pfizer Zwitterionic forms of trovafloxacin
US6114531A (en) * 1998-07-28 2000-09-05 Pfizer Inc. Process for preparing quinolone and naphthyridone carboxylic acids

Also Published As

Publication number Publication date
DE60001687D1 (de) 2003-04-24
ATE234835T1 (de) 2003-04-15
JP3465820B2 (ja) 2003-11-10
EP1057828B1 (en) 2003-03-19
DE60001687T2 (de) 2003-12-18
EP1057828A3 (en) 2001-05-16
PT1057828E (pt) 2003-07-31
EP1057828A2 (en) 2000-12-06
CA2311112A1 (en) 2000-12-04
BR0002577A (pt) 2001-01-02
JP2000344770A (ja) 2000-12-12
DK1057828T3 (da) 2003-07-14
US6239141B1 (en) 2001-05-29

Similar Documents

Publication Publication Date Title
ES2194677T3 (es) Suspensiones de trovafloxacina de administracion por via oral.
IL165715A0 (en) 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
TWI232219B (en) Compounds containing cyclohexane group, process for preparing them and pharmaceutical composition containing them
WO2003064431A3 (en) Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
EA199901014A1 (ru) C-4"-замещенные макролидные производные
BG101118A (en) Therapeutical compounds
EP1024145A3 (en) Novel azalides and methods of making same
MA25009A1 (fr) Procede de preparation de composes derives de la piperidine pour la preparation de compositions antibacteriennes
YU41500A (sh) Novi makrolidi
HK1077193A1 (en) Alpha-7 nicotinic receptor agonists and statins incombination
MXPA04012965A (es) Inhibidores virales.
EE200200208A (et) Oligosahhariidid, nende valmistamismeetod ja kasutamine ning farmatseutilised kompositsioonid
TR200102128T2 (tr) Ketolid antibiyotikler
NO996108L (no) 9-oksinerytromycinderivater
GT199900208A (es) Antibiòticos cetòlidos carbamato y carbazato.
AP2001002142A0 (en) 13-membered azalides and their use as antibiotic agents.
HUP0004282A2 (hu) 2-Halogén-6-0-szubsztituált ketolidszármazékok
ATE268337T1 (de) C11-carbamate von antibakteriellen makroliden
DE60208404D1 (de) Kreuzverquerte glycopeptid-cephalosporin-antibiotika
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
NO20042711L (no) Fremgangsmate for a behandle bakterielle infeksjoner ved anvendelse av gemifloksasin eller et salt derav et betalaktamantibiotikum
ITMI20021405A0 (it) Composizioni farmaceutiche per il trattamento di infezioni da patogeni dell'apparato respiratorio
BR9902049A (pt) Derivados 9a,11b-desidro de 9-oxima-3-ceto-6-o-metileritromicina.